Apimeds Pharmaceuticals US (APUS) Notes Payables (2023 - 2025)

Apimeds Pharmaceuticals US has reported Notes Payables for 3 years, with the latest figure at $7.1 million in Q4 2025.

• For the quarter ending Q4 2025, Notes Payables rose 2736.51% year-over-year to $7.1 million; the trailing twelve-month figure through Dec 2025 stood at $7.1 million (up 2736.51% YoY), and the FY2025 full-year result was $7.1 million, up 2736.51% from the prior year.
• Notes Payables for Q4 2025 stood at $7.1 million, up from $373620.0 in the prior quarter.
• The five-year high for Notes Payables was $7.1 million in Q4 2025, with the low at $250000.0 in Q4 2024.
• Historically, Notes Payables has averaged $2.0 million across 3 years, with a median of $320255.5 in 2023.
• Annual changes were most pronounced in 2024 — Notes Payables decreased 6.33% — and 2025, when it soared 2736.51%.
• Apimeds Pharmaceuticals US's Notes Payables stood at $266891.0 in 2023, then fell by 6.33% to $250000.0 in 2024, then soared by 2736.51% to $7.1 million in 2025.
• The last three Notes Payables figures came in at $7.1 million (Q4 2025), $373620.0 (Q1 2025), and $250000.0 (Q4 2024), per Business Quant data.